Ixekizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL-17a |
| Clinical data | |
| |
| Identifiers | |
1143503-69-8  | |
| None | |
| Chemical data | |
| Formula | C6492H10012N1728O2028S46 |
| 146.2 kDa | |
| (what is this?) (verify) | |
Ixekizumab is a humanized monoclonal antibody for the treatment of autoimmune diseases.[1] More specifically, it is being tested for the use in psoriasis. A Phase II clinical trial including patients with moderate to severe psoriasis has been completed,[2] and a Phase III open-label trial is under way as of November 2013.[3]
Ixekizumab was developed by Eli Lilly and Co.
Mechanism of action
Ixekizumab binds to interleukin 17 and blocks its action. This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which however binds to the interleukin-17 receptor.[2]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab" (PDF). American Medical Association.
- ↑ 2.0 2.1 "Neue Antikörper in der Pipeline". Pharmazeutische Zeitung (in German) (12). 2012.
- ↑ Clinical trial number NCT01624233 for "A Study in Japanese Participants With Moderate-to-Severe Psoriasis" at ClinicalTrials.gov